OptiNose Revenue and Competitors

Claim your profile

Location

$401.4M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • OptiNose's estimated annual revenue is currently $68.5M per year.(i)
  • OptiNose received $100.0M in venture funding in January 2018.
  • OptiNose's estimated revenue per employee is $334,098
  • OptiNose's total funding is $401.4M.
  • OptiNose's current valuation is $171.8M. (January 2022)

Employee Data

  • OptiNose has 205 Employees.(i)
  • OptiNose grew their employee count by -3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$41.4M206-6%N/AN/A
#2
$62.5M31135%N/AN/A
#3
$4.7M5730%N/AN/A
#4
$1110.5M5525-10%N/AN/A
#5
$45.4M226-1%N/AN/A
#6
$11.7M5816%N/AN/A
#7
$13.7M6842%N/AN/A
#8
$17.3M8637%N/AN/A
#9
$45.5M21912%N/AN/A
#10
$4.8M58-13%N/AN/A

OptiNose, Inc., established in 2010 and headquartered in Yardley, Pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ENT and Allergy specialists. Our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. We are unified by a shared mission: to improve lives. We do this while also creating great value for the healthcare system and great outcomes for our stakeholders. As innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. We operate with an overarching commitment to doing what is right. We are committed to working together as a team that chooses to live every day by core Company values that guide our daily behaviors, creating a foundation for future success. These include Friendship, Possibility Thinking, Fearless Conversations, Openness, Authenticity, Perseverance, and One Mission. We have a proven record of successful product development, a promising pipeline of new products, and a team of highly motivated and highly accomplished professionals working from offices in the U.S., U.K., and Norway. The Company's first products are based on patented Optinose Exhalation Delivery Systems. This technology is a platform for developing novel treatments that create meaningful new clinical benefits by enabling high and deep intranasal deposition of carefully selected medications. Optinose successfully developed its first product in the neurology therapeutic area (ONZETRA® Xsail®) and licensed North American commercialization rights to Avanir (subsequently acquired by Otsuka). In September 2017, Optinose received FDA approval for its second product, XHANCE(TM). XHANCE is an innovative product that delivers a topical steroid high and deep into nasal passages where inflammation can cause chronic symptoms. XHANCE is currently indicated for the treatment of nasal polyps in adults, and in 2018 we plan to initiate clinical trials in pursuit of a follow-on indication for chronic sinusitis, an indication for which we believe no other drugs are approved anywhere in the world. We are actively expanding our team to support this exciting product, including in commercial, supply chain, compliance, quality assurance, medical affairs, clinical research and other areas necessary for a rapidly growing fully integrated specialty pharmaceutical company. Beyond XHANCE, Optinose is evaluating pipeline opportunities that target large markets with significant unmet patient needs. These include opportunities in the ENT and allergy therapeutic areas and select nose-to-brain applications in the central nervous system therapeutic area (such as OPN-21 for narcolepsy and OPN-300 for autism and Prader-Willi syndrome). We have a near-term plan, a long-term vision, and a strong team to guide us. Keep an eye on us as we move forward to meet the needs of today's - and tomorrow's - healthcare challenges.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$401.4M

Total Funding

205

Number of Employees

$68.5M

Revenue (est)

-3%

Employee Growth %

$171.8M

Valuation

N/A

Accelerator

OptiNose News

2022-04-17 - Zacks Investment Research Upgrades OptiNose (NASDAQ:OPTN ...

According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for...

2022-04-13 - -$0.23 Earnings Per Share Expected for OptiNose, Inc. (NASDAQ ...

The company is scheduled to issue its next quarterly earnings results on Monday, January 1st. According to Zacks, analysts expect that OptiNose...

2022-04-06 - Optinose to Present at the Needham Virtual Healthcare Conference

About Optinose Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT)...

2021-11-18 - Optinose Announces Closing of $46.0 Million Public Offering of Common Stock

YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the closing of the previously announced underwritten public offering of 28,750,000 shares of its com ...

2021-07-28 - Optinose : Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million (Form 8-K)

Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020 Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to be at least $80 million Conference Call and Webcast t ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$50M24910%N/A
#2
$52.3M25233%N/A
#3
$75.8M43315%N/A
#4
$93.7M44738%N/A

OptiNose Funding

DateAmountRoundLead InvestorsReference
2014-08-05$UndisclosedC-1Avista Capital PartnersArticle
2015-10-07$30.0MUndisclosedArticle
2017-05-10$37.0MDFidelity Management and Research CompanyArticle
2018-01-03$100.0MUndisclosedAthyrium Capital Management, LPArticle